NASDAQ:FPRX
Delisted
Five Prime Therapeutics Stock News
$38.00
+0 (+0%)
At Close: May 27, 2022
Prime Time's Revival a Lesson for Biotech Investors
02:39pm, Wednesday, 24'th Mar 2021
In Amgen Inc.'s (NASDAQ:AMGN) recent agreement to buy small cancer drug developer Five Prime Therapeutics Inc. (NASDAQ:FPRX) for nearly $2 billion, there seems to be a message for investors in other s
Though Potential Bidders Moved Away, Amgen's Bid For Five Prime Outlasted 15 Suitors
02:29pm, Friday, 19'th Mar 2021
Earlier this month, biotech giant Amgen Inc (NASDAQ: AMGN) announced a $1.9 billion buyout of Five Prime Therapeutics Inc (NASDAQ: FPRX) that outlasted around 15 potential collaborators. Backg
Five Prime Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference Call
05:00pm, Tuesday, 09'th Mar 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference Call
Why Five Prime Therapeutics (FPRX) Might Surprise This Earnings Season
09:51am, Monday, 08'th Mar 2021
Five Prime Therapeutics (FPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Five Prime Therapeutics, Inc. - FPRX
10:02pm, Friday, 05'th Mar 2021
NEW YORK, March 5, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class A
Five Prime Therapeutics (FPRX) Stock Jumps 78.7%: Will It Continue to Soar?
08:23am, Friday, 05'th Mar 2021
Five Prime Therapeutics (FPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pr
FPRX Stock Price Increases 78.74% On Amgen Acquisition News
07:07pm, Thursday, 04'th Mar 2021
The stock price of Five Prime Therapeutics Inc (NASDAQ: FPRX) increased by 78.74% today. This is why it happened.
SHAREHOLDER ALERT: WeissLaw LLP Investigates Five Prime Therapeutics, Inc.
03:34pm, Thursday, 04'th Mar 2021
NEW YORK, March 4, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Five Prime Therapeutics, Inc. ("Five
Shareholder Alert: Ademi LLP Investigates whether Five Prime Therapeutics has obtained a Fair Price in its transaction with Amgen
02:04pm, Thursday, 04'th Mar 2021
MILWAUKEE, March 4, 2021 /PRNewswire/ -- Ademi LLP is investigating Five Prime (NASDAQ: FPRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Amgen. Click h
Amgen to Buy Oncology Start-Up Five Prime Therapeutics for $1.9 Billion
01:00pm, Thursday, 04'th Mar 2021
The big biotech wants to bolster its late-stage pipeline with a potential new stomach cancer treatment.
Why Five Prime Therapeutics Stock Is Skyrocketing Today
11:45am, Thursday, 04'th Mar 2021
Amgen is paying a premium to buy the small biotech.
FPRX Stock: The Huge Takeover News That Has Five Prime Therapeutics Shares Blasting Higher
11:44am, Thursday, 04'th Mar 2021
Five Prime Therapeutics (FPRX) stock is soaring higher on Thursday following news that Amgen (AMGN) is acquiring the company. The post FPRX Stock: The Huge Takeover News That Has Five Prime Therapeuti
Amgen Pays $1.9B For Five Prime Therapeutics Acquisition
11:35am, Thursday, 04'th Mar 2021
Amgen Inc (NASDAQ: AMGN) has agreed to acquire Five Prime Therapeutics Inc (NASDAQ: FPRX) for $38 per share in cash, representing an equity value of approximately $1.9 billion. The offer price o
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Five Prime Therapeutics, Inc. (NASDAQ: FPRX) to Amgen Inc. for $38.00 per share in
Amgen to buy Five Prime Therapeutics in a deal valued at $1.9 billion to boost cancer treatment portfolio
08:43am, Thursday, 04'th Mar 2021
Amgen Inc. announced Thursday an agreement to buy biotechnology company Five Prime Therapeutics Inc. in a cash deal valued at $1.9 billion. Five Prime shares were halted for news until 9 a.m.